At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 157 enrolled
Drug / intervention
CRLX101 +1 moredrug
Likely dose
CRLX101 15mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase 2, Study to Assess the Safety and Activity of CRLX101, a Nanoparticle Formulation of Camptothecin, in Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed One or Two Previous Regimens of Chemotherapy
In Brief
A Phase 2 clinical trial evaluating CRLX101 and Best Supportive Care for Non-Small Cell Lung Cancer. Completed, enrolled 157 participants across 25 sites in 2 countries.
Detailed Summary
The purpose of this study is to compare median overall survival of patients with advanced non-small cell lung cancer (NSCLC) treated with CRLX101 to patients treated with best supportive care (BSC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesRussia, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedJun 2011
Primary CompletionFeb 2013
Study CompletionOct 2014
TodayJul 2026
First PostedJun 27, 2011
Enrollment StartJun 1, 2011
Primary CompletionFeb 1, 2013
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.0 years ago
Interventions
CRLX101drug
CRLX101 is administered at 15mg/m2 IV every other week
Best Supportive Careother
best supportive care